Prestige Wealth Management Group LLC Acquires 179 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Prestige Wealth Management Group LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 65.8% during the third quarter, Holdings Channel.com reports. The fund owned 451 shares of the biopharmaceutical company’s stock after buying an additional 179 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Alnylam Pharmaceuticals were worth $124,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. TD Asset Management Inc increased its stake in Alnylam Pharmaceuticals by 6.0% in the 2nd quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock worth $119,055,000 after acquiring an additional 27,592 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after purchasing an additional 16,756 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 33.3% in the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after purchasing an additional 100,000 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Eagle Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 25.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after purchasing an additional 63,385 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ALNY has been the subject of a number of research reports. Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Raymond James upped their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,370 shares of company stock valued at $2,100,703. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ:ALNY opened at $253.91 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The firm has a market capitalization of $32.75 billion, a P/E ratio of -96.91 and a beta of 0.32. The stock has a 50 day moving average price of $268.29 and a 200-day moving average price of $247.45. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the prior year, the company earned $1.15 earnings per share. The business’s quarterly revenue was down 33.3% on a year-over-year basis. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.